Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRD-4730 in Heart Failure With Reduced Ejection Fraction (HFrEF)
NCT07750873Phase 2Recruiting
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CRD-4730 in heart failure with reduced ejection fraction (HFrEF) (4 arms), sponsored by Cardurion Pharmaceuticals. Primary endpoint: Change from Baseline in Composite Z-Score at 24 weeks. Started Jul 2026; status: recruiting.
02
Drugs
CRD-4730
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07750873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07750873.